Want to see IN:JUBLPHARMA full AI Analyst Report?
Jubilant Pharmova Limited (JUBLPHARMA) Ratios
Jubilant Pharmova Limited Ratios
IN:JUBLPHARMA's free cash flow for Q1 2027 was $0.00. For the 2027 fiscal year, IN:JUBLPHARMA's free cash flow was increased by $0.00 and operating cash flow was $0.00. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.62 | 1.65 | 2.05 | 2.12 | 2.20 |
| Quick Ratio | 1.13 | 1.13 | 1.36 | 1.32 | 1.40 |
| Cash Ratio | 0.50 | 0.50 | 0.50 | 0.57 | 0.62 |
| Solvency Ratio | 0.10 | 0.17 | 0.06 | 0.04 | 0.14 |
| Operating Cash Flow Ratio | 0.40 | 0.50 | 0.51 | 0.37 | 0.53 |
| Short-Term Operating Cash Flow Coverage | 4.09 | 3.74 | 3.93 | 2.20 | 1.81 |
| Net Current Asset Value | $ -43.18B | $ -29.41B | $ -22.51B | $ -20.02B | $ -11.65B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.23 | 0.21 | 0.32 | 0.33 | 0.32 |
| Debt-to-Equity Ratio | 0.51 | 0.44 | 0.67 | 0.68 | 0.60 |
| Debt-to-Capital Ratio | 0.34 | 0.30 | 0.40 | 0.41 | 0.38 |
| Long-Term Debt-to-Capital Ratio | 0.30 | 0.26 | 0.37 | 0.37 | 0.32 |
| Financial Leverage Ratio | 2.19 | 2.04 | 2.13 | 2.07 | 1.88 |
| Debt Service Coverage Ratio | 2.28 | 1.71 | 1.34 | 1.13 | 1.39 |
| Interest Coverage Ratio | 3.87 | 9.80 | 7.58 | 10.55 | 17.65 |
| Debt to Market Cap | 0.25 | 0.17 | 0.37 | 0.77 | 0.47 |
| Interest Debt Per Share | 241.50 | 187.08 | 248.12 | 242.85 | 209.63 |
| Net Debt to EBITDA | 1.85 | 1.57 | 3.42 | 4.12 | 2.07 |
| Profitability Margins | |||||
| Gross Profit Margin | 30.13% | 64.95% | 64.92% | 66.86% | 75.73% |
| EBIT Margin | 9.98% | 11.11% | 7.80% | 5.97% | 13.70% |
| EBITDA Margin | 15.29% | 14.48% | 11.84% | 10.29% | 17.39% |
| Operating Profit Margin | 9.90% | 32.56% | 30.80% | 31.60% | 41.90% |
| Pretax Profit Margin | 7.42% | 13.55% | 2.54% | 0.44% | 10.28% |
| Net Profit Margin | 4.81% | 11.60% | 1.15% | -0.97% | 6.75% |
| Continuous Operations Profit Margin | 4.80% | 11.56% | 1.08% | -1.03% | 6.74% |
| Net Income Per EBT | 64.89% | 85.60% | 45.22% | -219.42% | 65.66% |
| EBT Per EBIT | 74.95% | 41.63% | 8.26% | 1.40% | 24.55% |
| Return on Assets (ROA) | 2.57% | 6.58% | 0.67% | -0.55% | 4.14% |
| Return on Equity (ROE) | 5.62% | 13.42% | 1.42% | -1.13% | 7.78% |
| Return on Capital Employed (ROCE) | 6.31% | 22.24% | 21.37% | 21.15% | 30.58% |
| Return on Invested Capital (ROIC) | 3.99% | 18.37% | 8.84% | -47.59% | 18.87% |
| Return on Tangible Assets | 3.49% | 9.21% | 0.96% | -0.78% | 6.07% |
| Earnings Yield | 3.08% | 5.76% | 0.85% | -1.37% | 6.70% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.73 | 8.10 | 5.36 | 5.98 | 5.37 |
| Payables Turnover | 4.69 | 2.52 | 2.75 | 2.53 | 2.62 |
| Inventory Turnover | 4.70 | 2.25 | 1.80 | 1.46 | 1.16 |
| Fixed Asset Turnover | 1.20 | 1.40 | 1.82 | 1.87 | 2.20 |
| Asset Turnover | 0.53 | 0.57 | 0.58 | 0.56 | 0.61 |
| Working Capital Turnover Ratio | 5.55 | 4.26 | 3.37 | 3.22 | 3.21 |
| Cash Conversion Cycle | 47.07 | 62.94 | 137.58 | 166.30 | 244.23 |
| Days of Sales Outstanding | 47.24 | 45.03 | 68.12 | 61.06 | 68.02 |
| Days of Inventory Outstanding | 77.70 | 162.54 | 202.39 | 249.25 | 315.47 |
| Days of Payables Outstanding | 77.86 | 144.64 | 132.93 | 144.01 | 139.26 |
| Operating Cycle | 124.93 | 207.58 | 270.51 | 310.31 | 383.49 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 63.93 | 67.50 | 61.23 | 41.51 | 52.61 |
| Free Cash Flow Per Share | -27.53 | -2.74 | 4.64 | -9.66 | 14.92 |
| Dividend Paid and CapEx Coverage Ratio | 0.66 | 0.90 | 0.99 | 0.74 | 1.23 |
| Capital Expenditure Coverage Ratio | 0.70 | 0.96 | 1.08 | 0.81 | 1.40 |
| Operating Cash Flow Coverage Ratio | 0.28 | 0.39 | 0.27 | 0.18 | 0.26 |
| Operating Cash Flow to Sales Ratio | 0.12 | 0.15 | 0.14 | 0.11 | 0.14 |
| Free Cash Flow Yield | -3.37% | -0.30% | 0.81% | -3.47% | 3.84% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 32.46 | 17.31 | 118.23 | -72.75 | 14.93 |
| Price-to-Sales (P/S) Ratio | 1.56 | 2.01 | 1.36 | 0.71 | 1.01 |
| Price-to-Book (P/B) Ratio | 1.82 | 2.33 | 1.68 | 0.82 | 1.16 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -29.66 | -334.81 | 123.85 | -28.86 | 26.01 |
| Price-to-Operating Cash Flow Ratio | 12.77 | 13.58 | 9.38 | 6.72 | 7.38 |
| Price-to-Earnings Growth (PEG) Ratio | -0.62 | 0.02 | -0.52 | 0.63 | -0.54 |
| Enterprise Value Multiple | 12.07 | 15.47 | 14.91 | 10.99 | 7.87 |
| Enterprise Value | 152.84B | 162.07B | 118.26B | 71.01B | 83.91B |
| EV to EBITDA | 12.07 | 15.47 | 14.91 | 10.99 | 7.87 |
| EV to Sales | 1.85 | 2.24 | 1.76 | 1.13 | 1.37 |
| EV to Free Cash Flow | -35.04 | -372.57 | 160.67 | -46.17 | 35.32 |
| EV to Operating Cash Flow | 15.09 | 15.12 | 12.18 | 10.75 | 10.02 |
| Tangible Book Value Per Share | 188.89 | 163.76 | 120.64 | 126.43 | 134.88 |
| Shareholders’ Equity Per Share | 447.64 | 393.82 | 342.53 | 339.26 | 334.07 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.35 | 0.15 | 0.57 | 3.33 | 0.34 |
| Revenue Per Share | 522.54 | 455.50 | 422.52 | 394.71 | 385.05 |
| Net Income Per Share | 25.15 | 52.85 | 4.86 | -3.83 | 26.00 |
| Tax Burden | 0.65 | 0.86 | 0.45 | -2.19 | 0.66 |
| Interest Burden | 0.74 | 1.22 | 0.33 | 0.07 | 0.75 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.20 | 0.32 | 0.33 | 0.35 | 0.33 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 2.54 | 1.28 | 12.60 | 23.78 | 1.33 |
Currency in INR
